Toute l’ingéniosité et la vitalité d’Oncodesign via notre espace ressources

Le processus de découverte et de développement d’une molécule est complexe, long et couteux. Avant de prendre une décision sur l’offre qui répond au mieux à votre besoin, nous vous proposons des ressources scientifiques en ligne, nos dernières actualités pour mieux nous connaitre et nous rencontrer. Nos experts sont également à votre disposition pour vous aider et vous accompagner dans votre programme de recherche et développement.

Filtrer par BU ou service
  • Tous
  • Corporate
  • Service
  • Biotech
  • I.A.
  • Programme Homing
  • Finance
  • RH
Filtrer par BU ou service
Filtrer par catégorie
  • Tous
  • Webinaires
  • Posters
  • Publications scientifiques
  • Communiqué de Presse
  • Couverture presse
  • Media Kit
  • Actualités
Filtrer par catégorie
loader

Ressources Scientifiques

Webinaires

Service
04/05/2021

[Webinaire] [EN] Oncology and Immuno-Oncology Precision Medicine: From Hit-Finding to Pre-Clinical Candidate Selection

Lire la suite
Service
04/05/2021

[EN] Oncology and Immuno-Oncology Precision Medicine: From Hit-Finding to Pre-Clinical Candidate Selection

Lire la suite
Service
19/11/2020

[Webinaire] [EN] Cancer Vaccine toolbox: innovative strategies for prophylactic or therapeutic vaccines

Lire la suite
19/11/2020

[EN] Cancer Vaccine toolbox: innovative strategies for prophylactic or therapeutic vaccines

Lire la suite
Service
12/11/2020

[Webinaire] [FR] How do we keep you in the race of COVID-19?

Lire la suite
Service
16/10/2020

[Webinaire] [EN] How do we keep you in the race of COVID-19?

Lire la suite
Service
16/10/2020

[EN] How do we keep you in the race of COVID-19?

Lire la suite
Service
22/09/2020

[Webinaire] [EN] MRI: going beneath the surface in preclinical oncology

Lire la suite
22/09/2020

[EN] MRI: going beneath the surface in preclinical oncology

Lire la suite
Service
16/07/2020

[Webinaire] [EN] NEW INTERACTIVE PANEL WEBINAR DRIVE™: Brothers in Arms to support small molecule drug discovery from Hit to IND

Lire la suite
Service
07/07/2020

[WEBINAIRES] CAHIER DE VACANCES DE L’ÉTÉ

Lire la suite
Service
07/07/2020

[EN] NEW INTERACTIVE PANEL WEBINAR DRIVE™: Brothers in Arms to support small molecule drug discovery from Hit to IND

Lire la suite
Service
02/07/2020

[Webinaire] [EN] How to better predict your drug efficacy to combat liver diseases?

Lire la suite
02/07/2020

[EN] How to better predict your drug efficacy to combat liver diseases?

Lire la suite
27/06/2020

[EN] How to assess the interplay between tumor, microbiota and therapies? A comprehensive platform to investigate bacteria as immuno-modulating vectors or agents.

Lire la suite
Service
26/06/2020

[Webinaire] [EN] How to assess the interplay between tumor, microbiota and therapies? A comprehensive platform to investigate bacteria as immuno-modulating vectors or agents.

Lire la suite
Service
18/06/2020

[Webinaire] [EN] How to recruit immune cells against tumor? Bispecific compounds are the key for new oncology therapeutic strategy

Lire la suite
18/06/2020

[EN] How to recruit immune cells against tumor? Bispecific compounds are the key for new oncology therapeutic strategy

Lire la suite
Service
28/05/2020

[Webinaire] [EN] How to better predict the effect of cancer immunotherapy? Tailored-made humanized mouse models are the key solution!

Lire la suite
20/05/2020

[EN] How to better predict the effect of cancer immunotherapy? Tailored-made humanized mouse models are the key solution!

Lire la suite
Service
28/04/2020

[Webinaire] [EN] How to trigger the immune response in anti-tumor therapy? A comprehensive in vitro to in vivo screening platform to identify ICD inducers

Lire la suite
28/04/2020

[EN] How to trigger the immune response in anti-tumor therapy? A comprehensive in vitro to in vivo screening platform to identify ICD inducers

Lire la suite
Service
03/04/2020

[Webinaire] [EN] Simple services or solutions provider: what is the best option to support your drug discovery efforts at preclinical stage?

Lire la suite
02/04/2020

[EN] Simple services or solutions provider: what is the best option to support your drug discovery efforts at preclinical stage?

Lire la suite
Service
29/11/2019

[Webinaire] [EN] How to kick-start the immune response in anti-tumor therapy? A unique screening platform to identify ICD inducers

Lire la suite
28/11/2019

[EN] How to kick-start the immune response in anti-tumor therapy? A unique screening platform to identify ICD inducers

Lire la suite
Service
29/10/2019

[Webinaire] [EN] Conquering sensitive CYPs, UGTs and transporters protein quantification with QTAP analysis

Lire la suite
24/10/2019

[EN] Conquering sensitive CYPs, UGTs and transporters protein quantification with QTAP analysis

Lire la suite
Service
27/09/2019

[Webinaire] [EN] Preclinical assessment of Targeted Radionuclide Therapy: a step further toward precision medicine

Lire la suite
26/09/2019

[EN] Preclinical assessment of Targeted Radionuclide Therapy: a step further toward precision medicine

Lire la suite
23/05/2019

[EN] Make it cyclic: A paradigm for the discovery of selective kinases inhibitors “Nanocyclix”

Lire la suite
Service
25/02/2019

[Webinaire] [EN] Supporting your immuno-onco drug discovery programs from hit identification to candidate selection!

Lire la suite
21/02/2019

[EN] Supporting your immuno-onco drug discovery programs from hit identification to candidate selection!

Lire la suite
Service
04/02/2019

[Webinaire] [EN] How to better predict the effect of cancer immunotherapy? Tailored-made humanized mouse models are the key solution!

Lire la suite
29/01/2019

[EN] How to better predict the effect of cancer immunotherapy? Tailored-made humanized mouse models are the key solution!

Lire la suite
Service
19/07/2018

[Webinaire][EN] Drug biodistribution & efficacy: how can radiolabeling a molecule make the difference?

Lire la suite
12/07/2018

[EN] Drug biodistribution & efficacy: how can radiolabeling a molecule make the difference?

Lire la suite
Service
01/12/2017

[Webinaire][EN] Pharmaco-imaging: potential in translational research, a case study of EGFR PET radiotracer

Lire la suite
01/03/2017

[EN] Pharmaco-imaging: potential in translational research, a case study of EGFR PET radiotracer

Lire la suite
01/06/2016

[EN] Integrating pharmacology and imaging in preclinical oncology drug development

Lire la suite
05/10/2015

[EN] Cutting-edge humanized mouse models to predict the patient response to cancer treatments

Lire la suite
19/06/2014

[EN] Predictive Cancer Models for Better Precision Medicine

Lire la suite
Découvrez tous nos Webinaires

Posters

Service
16/04/2021

AACR April, 2016 – Efficacy of PD-1/PD-L1 pathway disruptors in syngeneic models

Read
Service
16/04/2021

AACR April, 2016 – Enhanced antitumor activity achieved by combining the oncolytic peptide LTX-315 with anti-PD-L1 antibody

Read
Service
04/01/2021

mAb formulation development and stability studies through complementary and orthogonal analytical methods

Voir
Service
02/09/2020

Development of an immunogenicity assay for Anti-Drug Antibody (ADA) detection directed against an oligonucleotide CpG D35 using ECL technology (MSD)

Read
Service
02/09/2020

mAb formulation development and stability studies through complementary and orthogonal analytical methods

Lire
02/09/2020

NANOCYCLIX® ALK2 INHIBITORS TO OVERCOME CANCER INDUCED ANEMIA

Lire
Service
02/09/2020

Live Biotherapeutic MRx0518 as a modulator of immune responses in intestinal tissue and breast tumor microenvironment

Lire
Service
02/09/2020

Development of a panel of breast cancer patient-derived xenograft models (PDX) with estrogen independence and/or acquired resistance to endocrine treatment

Lire
Service
02/09/2020

Modelling liver diseases from acute and chronic injury to hepatocellular carcinoma for development of new treatments

Lire
Service
02/09/2020

ADCs optimization led to a significant anti-tumoral activity in lymphoma and breast tumor xenograft mouse models

Lire
Service
06/01/2020

Live Biotherapeutic MRx0518 as a modulator of immune responses in intestinal tissue and breast tumor microenvironment

Voir
06/01/2020

Novel fluorescent probes evaluated in an orthotopic pancreatic PDX model

Voir
Service
06/01/2020

Development of a panel of breast cancer patient-derived xenograft models (PDX) with estrogen independence and/or acquired resistance to endocrine treatment

Voir
Biotech
01/01/2020

NANOCYCLIX® ALK2 INHIBITORS TO OVERCOME CANCER INDUCED ANEMIA

Voir
Service
01/01/2020

Modelling liver diseases from acute and chronic injury to hepatocellular carcinoma for development of new treatments

Voir
Service
01/01/2020

ADCs optimization led to a significant anti-tumoral activity in lymphoma and breast tumor xenograft mouse models

Voir
Service
07/02/2019

AACR Atlanta – Customized methodology to investigate immuno-oncology drugs using humanized mouse models

Voir
Service
07/02/2019

AACR Atlanta – Targeted external or internal radiotherapy in combination with immunotherapies and companion imaging diagnostics

Voir
Service
07/02/2019

AACR Atlanta – Induction of immunogenic cell death and enhancement of dendritic cell function

Read
Service
07/02/2019

AACR Atlanta – Immune Checkpoint Blockade and Autoimmune Diseases

Read
Service
07/02/2019

Immuno-Oncology Summit Europe – Development of Pre-Clinical Assays to Support Drug Discovery Programs in Immuno-Oncology

Read
Service
18/06/2018

17th Annual World Preclinical Congress – Presentation

Read
Service
18/06/2018

17th Annual World Preclinical Congress – SMPT: a tool for translational research

Read
Service
18/06/2018

17th Annual World Preclinical Congress – Humanized mouse models for evaluation of cancer therapies

Read
Service
18/06/2018

17th Annual World Preclinical Congress – Development of a high throughput in vitro screening platform to identify novel inducers of immunological cell death

Read
Service
04/06/2018

AACR 2018 – Humanized mouse models for evaluation of cancer therapies

Read
Service
04/06/2018

AACR 2018 – Development of a high throughput in vitroscreening platform to identify novel inducers of immunological cell death

Read
Service
04/06/2018

AACR 2018 – Morab-202 A Folate Receptor Alpha-Targeted Antibody-Drug Conjugate Shows A Highly Potent Activity Against A Panel Of Frα-Expressing Tumors

Read
Service
04/06/2018

AACR 2018 – Modulating T cell immunity in tumors by targeting tumor-associated antigens

Read
Service
14/04/2018

19th Drug Discovery Summit – Development of a high throughput in vitro screening platform to identify novel inducers of immunological cell death

Read
Service
01/01/2018

EFMC-ISMC 2018 XXV – EFMC International Symposium on Medicinal Chemistry

Read
Service
01/01/2018

Bio IT Congress – OncoSNIPE, Al initiative designed to identify and characterize patients resistant or non responder to cancer treatments

Read
Service
02/01/2017

AACR 2017 – Antitumor activity of CMP-001 (TLR9 agonist) alone or combined with immune modulators in syngeneic tumor modelsdels of brain tumors :

Read
Service
02/01/2017

AACR 2017 – Overcoming PD-1 targeting antibody resistance using combination strategieshuman lung tumors using DCE-MRI and FLOOD MRI

Read
Service
02/01/2017

AACR 2017 – Preclinical proof of concept for the first [18F]-Nanocyclix®TKI-PET radiotracer targeting activated EGFR positive lung tumors

Read
Service
02/01/2017

ISRS 2017 – Radiosynthesis of the first [18F]-Nanocyclix® TKI-PET radiotracer targeting activated EGFR positive lung tumors

Read
Service
02/01/2017

WPC 2017 – From syngeneic to humanized murine models: addressing the needs for novel immunotherapies

Read
Service
02/01/2017

RICT 2017 – Identification of potent ALK2 inhibitors as potential treatment for stone man syndrome

Read
Service
02/01/2017

EFMC-ASMC’17 – Application of the Nanocyclix® technology to identify clinically relevant PET tracerspositive lung tumors

Read
Service
02/01/2017

Widespread brain distribution of SGSH enzyme in canine brain following white matter injection of LYS-SAF302, an AAVrh.10-SGSH vector

Read
Service
02/01/2017

EORTC 2017 – « Anti tumour activity of new antibody drug conjugate (ADC) with eribulin in triple negative breast cancer (TNBC) patient-derived xenograft (PDX) »

Read
Service
02/01/2017

EANM 2017 –  » In vitro and in vivo evaluation of two enantiomers of Nanocyclix® EGFR targeted PET radiotracer”

Read
Service
02/01/2017

AACR 2017 – IMODI initiative : a novel holistic and integrative approach with patient-derived tumor models against pancreatic cancer

Read
Service
29/11/2016

EORTC, 2016 – Beneficial outcome of combination therapy with 4 -1BB mAb targeting antibody

Read
Service
14/11/2016

WPC November, 2016 – Evaluation of immuno-oncology related treatments using highly characterized syngeneic mouse tumor models

Read
Service
14/11/2016

WPC November, 2016 – Immuno-oncology therapeutics technological progression toward a huge preclinical challenge of humanizing the immune component in mice

Read
Service
14/06/2016

WPC June, 2016 – From syngeneic to humanized mouse models: addressing the needs for novel immunotherapies

Read
Service
16/04/2016

AACR April, 2016 – Humanized mouse models for evaluation of cancer therapies

Read
Service
16/04/2016

AACR April, 2016 – Innovative and predictive models against cancer: an IMODI integrative approach

Read
Service
16/04/2016

AACR February, 2016 – A Novel Holistic and Integrative Approach with Patient-Derived Tumor Models

Read
Service
04/01/2016

EANM, 2016 – Pharmacokinetic of tumor FDG uptake in subcutaneous and orthotopic preclinical models of breast cancer

Read
Service
21/10/2015

Ex-vivo inhibition of LRRK2 phosphorylation by a new kinase inhibitor in peripheral blood cells of subjects with and without G2019S LRRK2 mutation

Read
Service
01/01/2015

EORTC 2015 – Tumor infiltrating lymphocytes as a biomarker of response for CTLA-4 targeting therapies

Read
Service
01/01/2015

EORTC 2015 – Efficacy of PD-1 / PD-L1 pathway disruptors in syngeneic models

Read
Service
01/01/2015

AACR 2015 – Evaluation of immuno-oncology related treatment in syngenic mouse models

Read
Service
01/01/2015

AACR 2015 – In vivo TK-NOG liver-humanized model to predict patient pharmacological profile of anti-cancer agents

Read
Service
01/01/2015

Identification and characterization of a novel LRRK2 kinase inhibitor: ODS2005294

Read
Service
05/04/2014

AACR 2014 – Mouse renca renal cell carcinoma syngeneic model to evaluate efficacy of novel antisense oligonucleotides targeting transforming growth factor beta (TGF-β) isoforms

Read
Service
01/01/2014

AACR 2014 – Biodistribution and antitumor efficacy study of novel Her2-targeting DARPins

Read
Service
01/01/2014

AACR 2014 – Pharmacodynamic evaluation of ADCC mediated effects in humanized IL2 or IL15 NOG mice models

Read
Service
01/01/2014

Evaluation of 111In/177Lu antibody fragments for diagnostic and therapeutic purpose

Read
Service
01/01/2014

AACR 2014 – Pharmaco-imaging study of the effects of Debio1143, a new orally available IAP inhibitor, in a triple-negative breast cancer model

Read
Service
01/01/2013

EORTC 2013 – In vivo ADCC-Mediated Antitumor Activity Study with New Preclinical Humanized Models

Read
Service
01/01/2013

AACR 2013 – Use of Humanized NOG Mice within the Pre-Clinical Development of New Human Specific Therapies

Read
Service
01/01/2013

AACR 2013 – Establishment and Characterization of Human Skingraft Model in Immunodeficient Mice

Read
Service
01/01/2013

AACR 2013 – Development Program of Patient Tumor Tissue Bank to Support the Drug and Target Discovery

Read
Service
01/01/2013

AACR 2013 – Antiprogestin Drug Developement: In Vitro Validation of a Potential Clinical Biomarker

Read
Service
02/01/2012

2012 – PDX to correlate pathways abnormalities with response to anti-EGFR therapy

Read
Service
02/01/2012

2012 – Characterization of CIEA NOG® mice reconstituted with human CD34+ stem cells (HSCs) or mature PBMCs

Read
Service
02/01/2012

2012 – Preclinical Evaluation of Indium 111 Radiololabeled Trastuzumab and Pertuzumab for HER2-positive Breast Cancer Molecular Imaging

Read
Service
02/01/2012

2012 – Measurement of tumor vascular integrity changes in an orthotopic glioma model in rats induced by antiangiogenic treatment using DCE-MRI

Read
Service
02/01/2012

2012 – Enhanced paclitaxel delivery to tumors using a new lipid nanocapsule-based formulation

Read
Service
02/01/2012

2012 – Evaluation of immune response in preclinical settings

Read
Service
02/01/2012

2012 – Development of Bruton’s Tyrosine Kinase (Btk) inhibitor – ONO-WG-307, a potential treatment for B-cell malignancies

Read
Service
01/01/2011

2011 – Humanized SCID mouse as tool for evaluation of B cell targeting therapies

Read
Service
01/01/2011

2011 – Extensive use of fresh patient-derived tumor samples for drug discovery and drug positioning in oncology

Read
Service
01/01/2011

2011 – DOTA-conjugated antibodies for scintigraphic evaluation of new anti-cancer treatments

Read
Service
01/01/2011

2011 – Modeling the sequence-sensitive gemcitabine-docetaxel combination using the Virtual Tumor

Read
Service
01/01/2010

2010 – PET Study with [11C]Choline and its derivates in the human hormonedependent prostate cancer rat-xenograft-tumor-model PAC120

Read
Service
01/01/2010

2010 – Amuvatinib (MP-470), a multi-targeted tyrosine kinase inhibitor and DNA repair suppressor, synergizes with Etoposide (VP-16) in Small Cell Lung Cancer (SCLC) cell lines and xenografts

Read
Service
01/01/2010

2010 – In vivo characterisation of orthotopic prostate tumor and healthy rat prostate metabolism using 1H-MRS at 4.7 T

Read
Service
01/01/2010

2010 – Oncodesign translational drug discovery process

Read
Service
01/01/2010

2010 – Development of a fully human immune system in NOD/SCID/ IL2Rgamma (NSG) mice for oncology research purpose

Read
Service
01/01/2010

2010 – The dual selective VEGFR-FGFR kinases inhibitor E-3810 decreases tumor perfusion and inhibits tumor growth: an analyis using dynamic contrast-enhanced magnetic resonance imaging

Read
Service
01/01/2010

2010 – In vivo study of serum cancer biomarkers and pain-induced bone metastasis of human prostate tumor in Nude rats

Read
Service
01/01/2010

2010 – CReMEC initiative: Characterization of patient-derived colorectal tumor models and correlation with patient profile

Read
Service
01/01/2010

2010 – Antitumor activity of EP80061, a small-glyco drug in preclinical studies

Read
Service
01/01/2009

2009 – Is there a species specific uptake of [11C]Choline and [18F]FECh in xenograft-models in prostate cancer ?

Read
Service
01/01/2009

2009 – Small Animal PET/MRI: an in vivo study in oncology using a U-87 MG mouse glioma model

Read
Service
01/01/2009

2009 – Humanized mouse model for in vivo antibody-dependent cell-mediated cytotoxicity evaluation

Read
Service
01/01/2009

2009 – DCE-MRI as a tool to detect tumor vasculature normalization by E7820, a novel angiogenesis inhibitor

Read
Service
01/01/2009

2009 – The VEGF antagonist PRS-050 decreases vascular permeability in tumors and inhibits tumor growth: an analysis using dynamic contrast-enhanced magnetic resonance imaging

Read
Service
01/01/2009

2009 – DDS-06E A novel oral pH-sensitive micellar formulation of SN38: Effect of dosing regimen on efficacy and tolerability using a human colon xenograft model

Read
Service
01/01/2009

2009 – Prostate cancer metabolism assessment by proton magnetic resonance spectroscopy (1H-MRS) and high resolution magic angle spinning spectroscopy (1H-HRMAS) in experimental rat models

Read
Service
01/01/2009

2009 – CReMEC initiative: Establishment and characterization of new in vivo models of human colorectal cancers

Read
Service
01/01/2008

2008 – Enhanced drug delivery to brain tumors with a new paclitaxel-peptide conjugate

Read
Service
01/01/2008

2008 – Enhanced efficacy of therapy of anti-CD20 antibody with Locked Nucleic Acid antisense oligonucleotide targeting Bcl-2 in human Burkitt’s lymphoma xenografts

Read
Service
01/01/2008

2008 – The steroid sulfatase inhibitor BN83495 inhibits E1S-stimulated growth of DMBA-induced mammary tumours in rat

Read
Service
01/01/2008

2008 – Evaluation of PET tracer uptake in mouse xenograft models of hormone-dependent prostate cancer

Read
Service
01/01/2008

2008 – Evaluation of tumor response to carmustine and sorafenib with magnetic resonance imaging in an orthotopic human glioblastoma model xenografted in nude rats

Read
Service
01/01/2008

2008 – Optimization of engraftment of human NK cells in NOD-SCID mice

Read
Service
01/01/2008

2008 – Mechanism of action of a human anti-CD70 antibody-MGBA conjugate and efficacy in a nude rat model of renal carcinoma

Read
Service
01/01/2008

2008 – Evaluation of early response to temozolomide and radiotherapy with magnetic resonance imaging and proton magnetic resonance spectroscopy in human glioma models in nude rats

Read
Découvrez tous nos Posters

Publications scientifiques

Service
01/01/2015

Chemotherapy Resistant Human Acute Myeloid Leukemia

Read
Service
14/01/2014

IFN-gamma AU-rich element removal promotes chronic IFN-gamma expression and autoimmunity in mice

Read
Service
01/01/2014

Biopharma Dealmakers – Macrocycle discovery complements a robust preclinical program

Read
Service
01/07/2013

IFN-gamma AU-rich element removal promotes chronic IFN-gamma expression and autoimmunity in mice

Lire
Service
07/01/2013

2013 – Integrated PET/MRI in preclinical studies state of the art

Lire
Service
01/01/2013

2013 – Integrated PET/MRI in preclinical studies state of the art

Read
Service
02/10/2012

2012 – Characterization of a Large Panel of Patient-derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer

Lire
Service
23/04/2012

2012 – DOTAGA-Trastuzumab. A New Antibody Conjugate Targeting HER2/ Neu Antigen for Diagnostic Purposes

Read
Service
02/04/2012

2012 – DOTAGA-Trastuzumab. A New Antibody Conjugate Targeting HER2/ Neu Antigen for Diagnostic Purposes

Lire
Service
01/02/2012

2012 – Is T2* Enough to Assess Oxygenation? Quantitative Blood Oxygen Level–Dependent Analysis in Brain Tumor

Lire
Service
01/02/2012

2012 – Is T2* Enough to Assess Oxygenation? Quantitative Blood Oxygen Level–Dependent Analysis in Brain Tumor

Read
Service
01/01/2012

2012 – In-vivo Metabolic Characterization of Healthy Prostate and Orthotopic Prostate Cancer in Rats Using Proton Magnetic Resonance Spectroscopy at 4.7T

Read
Service
01/03/2011

2011 – Imaging Cancer Biomarkers

Read
Service
01/03/2011

2011 – From a personal point of view

Read
Service
01/12/2010

2010 – Preferential Effect of Synchrotron Microbeam Radiation Therapy on Intracerebral 9L Gliosarcoma Vascular Networks

Read
Service
21/11/2010

2010 – Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal in vivo and ex vivo study.

Read
Service
29/10/2010

2010 – Characterization of tumor angiogenesis in rat brain using iron-based vessel size index MRI in combination with gadolinium-based dynamic contrast-enhanced MRI

Read
Service
01/02/2010

2010 – SKH-1 mouse skin painting: a short-term assay to evaluate the tumorigenic activity of cigarette smoke condensate

Read
Service
01/01/2009

2009 – Cytotoxic spirostane-type saponins from the roots of Chlorophytum borivilianum

Read
Service
01/01/2008

2008 – Integrating pharmacology and imaging in preclinical oncology drug development

Read
Service
11/10/2007

2007 – Saponins from the roots of Nylandtia spinosa

Read
Service
14/02/2007

2007 – VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases F. Haghighi Rad, H. Le Buanec, S. Paturance, P. Larcier, P. Genne, B. Ryffel, A. Bensussan, B. Bizzini, R. Gallo, D. Zagury and G. Uzan PNAS – Online publication

Read
Service
01/12/2006

2006 – Triterpene saponins from Schefflera abyssinica L. Tapondjou, A.C. Mitaine-Offer, T. Miyamoto, H. Lerche, J.F. Mirjolet, N. Guilbaud, M.A. Lacaille-Dubois Biochem. Syst. and Eco., 2006 Dec, 34(12): 887-9 EN SAVOIR PLUS

Read
Service
01/09/2006

2006 – KRN951, a highly potent and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has anti-tumor activities and affects functional vascular properties

Read
Service
01/07/2006

2006 – Triterpene saponins from Eryngium campestre

Read
Service
01/01/2006

2006 – Medaka simplet (FAM53B) belongs to a family of novel vertebrate genes controlling cell proliferation

Read
Service
12/05/2005

2005 – A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein

Read
Service
26/04/2005

2005 – Pursaethosides A-E, triterpene saponins from Entada pursaetha

Read
Service
04/04/2005

2005 – Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor

Read
Service
21/01/2005

2005 – Activation of GPR54 promotes cell cycle arrest and apoptosis of human tumor cells through a specific transcriptional program not shared by other Gq-coupled receptors

Read
Service
01/01/2005

2005 – Role of non invasive animal imaging in preclinical anticancer drug development (French review)

Read
Service
06/10/2003

2003 – Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids

Read
Service
23/07/2003

2003 – Oncoprotein expression of E6 and E7 does not prevent 5-fluorouracil (5FU) mediated G1/S arrest and apoptosis in 5FU resistant carcinoma cell lines

Read
Service
12/07/2003

2003 – Rationale supporting the use of vasoconstrictors for intraperitoneal chemotherapy with platinum derivatives (Review)

Read
Service
09/01/2003

2003 – Characterization of human Smg5/7a: a protein with similarities to Caenorhabditis elegans SMG5 and SMG7 that functions in the dephosphorylation of Upf1

Read
Service
01/11/2002

2002 – Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts

Read
Service
01/07/2002

2002 – Radiation could induce p53-independent and cell cycle-unrelated apoptosis in 5-fluorouracil radiosensitized head and neck carcinoma cells

Read
Service
13/06/2002

2002 – Improved tumor selectivity of radiolabeled peptides by receptor and antigen dual targeting in the neurotensin receptor model

Read
Service
01/05/2002

2002 – G(1)/S but not G(0)/G(1)cell fraction is related to 5-fluorouracil cytotoxicity

Read
Service
01/02/2002

2002 – Europium-labeled epidermal growth factor and neurotensin: novel probes for receptor-binding studies

Read
Service
01/12/2001

2001 – Constitutive NF-kappaB activity influences basal apoptosis and radiosensitivity of head-and-neck carcinoma cell lines

Read
Service
07/09/2001

2001 – Evidence for a pioneer round of mRNA translation: mRNAs subject to nonsense-mediated decay in mammalian cells are bound by CBP80 and CBP20

Read
Service
15/03/2001

2001 – Involvement of caspase-2 long isoform in Fas-mediated cell death of human leukemic cells

Read
Service
21/01/2001

2001 – Identification and characterization of human orthologues to Saccharomyces cerevisiae Upf2 protein and Upf3 protein (Caenorhabditis elegans SMG-4)

Read
Service
11/01/2001

2001 – Modulation of apoptosis by procaspase-2 short isoform : selective inhibition of chromatin condensation, apoptotic body formation and phosphatidylserine externalisation

Read
Service
01/01/2001

2001 – Nonsense-mediated mRNA decay: insights into mechanism from the cellular abundance of human Upf1, Upf2, Upf3, and Upf3X proteins (Review)

Read
Service
25/12/2000

2000 – Enhanced targeting specificity to tumor cells by simultaneous recognition of two antigens

Read
Service
20/12/2000

2000 – Preclinical evaluation of aromatase inhibitors antitumor activity (Review in French)

Read
Service
14/12/2000

2000 – Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes

Read
Service
01/02/2000

2000 – Effect of cyclosporin at various concentrations on dexamethasone intracellular uptake in multidrug resistant cells

Read
Service
15/07/1999

1999 – MDR1 and thymidylate synthase gene expressions in advanced breast cancer: relationships to P53 mutations, response to primary chemotherapy and survival

Read
Service
15/07/1998

1998 – S9788 modulates P-gp and MRP mediated MDR in doxorubicin resistant MCF7cells

Read
Service
14/07/1998

1998 – Multidrug resistance genes (MRP) and (MDR1) expression in small cell lung cancer xenografts : relationship with response to chemotherapy

Read
Service
01/07/1998

1998 – Thymidylate synthase expression and activity : relation to S-phase parameters and 5-fluorouracil sensitivity

Read
Service
10/10/1997

1997 – Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy

Read
Service
15/09/1997

1997 – Cytoskeleton alterations in MCF7R, a multidrug resistant human breast cancer cell line

Read
Service
11/07/1997

1997 – French multicentric evaluation of mdr1 gene expression by RT-PCR in leukemia and solid tumours. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours.

Read
Service
01/05/1997

1997 – Two RNA-binding domains determine the RNA-binding specificity of nucleolin

Read
Service
10/03/1997

1997 – Pretargeted radioimmunotherapy using (131) I-labelled bivalent hapten-bearing peptides

Read
31/10/1995

1995 – Adding a reverser (verapamil) to combined chemotherapy overrides resistance in small-cell lung cancer xenografts

Read
Service
09/10/1995

1995 – Circumvention of confluence-dependent resistance in a human multidrug-resistant colon cancer cell line

Read
Service
09/06/1995

1995 – The role of cell regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors

Read
Service
10/03/1995

1995 – Cinchonine administrated per os: efficient to circumvent P-glycoprotein mediated multidrug resistance in vivo

Read
Service
14/10/1994

1994 – Confluence dependent resistance to doxorubicin and E-cadherin expression in murine mammary cells

Read
Service
01/10/1994

1994 – Deleterious effect of serum proteins on the amphotericin B-induced potentiation of cisplatin in human colon cancer cells

Read
Service
09/04/1994

1994 – Liposomal mitoxantrone for the local treatment of peritoneal carcinomatosis induced by colon cancer cells in mouse

Read
Service
08/01/1994

1994 – Comparative effects of quinine and cinchonine in reversing multidrug resistance on human leukemic cell line K562/ADM

Read
Service
13/04/1993

1993 – Mdr 1 gene-expression and villin synthesis in a colon cancer cell line differentiated by sodium butyrate

Read
Service
15/05/1992

1992 – Cinchonine: a potent efflux inhibitor to circumvent anthracycline resistance in vivo

Read
Service
15/04/1992

1992 – Histological reactivity of monoclonal antibody against rat colon cancer cells on human and rat normal gut and colonic tumors

Read
Service
15/03/1992

1992 – Chimiothérapie expérimentale de carcinomatose péritonéale d’origine colique chez le rat (FR))

Read
Service
12/03/1992

1992 – Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells

Read
Service
15/10/1990

1990 – Mechanism of resistance of confluent human and rat colon cancer cells to anthracyclines: alteration of drug passive diffusion

Read
Service
15/10/1990

1990 – F11C antigen: a membrane marker able to distinguish two regressive and progressive variants from a rat colon adenocarcinoma

Read
Service
15/11/1989

1989 – Serum concentration of amiodarone required for an in vivo modulation of anthracycline resistance

Read
Service
09/10/1195

1995 – Cellular Pharmacology of azatoxins (Topoisomerase-II and tubulin inhibitors) in P-glycoprotein-positive and negative cell lines

Read
Service
01/07/1194

1994 – Mitoxantrone-Aracytine avec ou sans quinine dans le traitement des leucémies aiguës réfractaires ou en rechute (FR)

Read
Service

Biopharma Dealmakers – Macrocycle discovery complements a robust preclinical program

Lire
Service

Chemotherapy Resistant Human Acute Myeloid Leukemia

Lire
Découvrez toutes nos Publications scientifiques

Documentation

Presse

Communiqué de Presse

Finance
21/07/2021

Oncodesign annonce une forte augmentation de son chiffre d’affaires du 1er semestre 2021

Chiffre d’affaires Groupe en hausse de +33% à 15,8 M€. Succès pour le programme LRRK2. Position de trésorerie de 27 M€ au 30 juin 2021

Lire la suite
Corporate
05/07/2021

Oncodesign annonce la nomination d’Aline Aubertin en qualité d’administratrice indépendante du Conseil d’administration

Oncodesign renforce son Conseil d’Administration avec la nomination d’Aline Aubertin en qualité de nouvelle administratrice indépendante.

Lire la suite
SOLO-Pharmaco-Imaging
Service
01/07/2021

Oncodesign, Covalab, CheMatech et ABX-CRO lancent DRIVE™-MRT

Découvrez l'alliance d'experts en radiopharmaceutiques : une offre innovante en développement thérapeutique en médecine nucléaire depuis la validation de cibles thérapeutiques, la génération de vecteurs biologiques radiomarqués, l'optimisation de leads, la génération de candidats médicaments jusqu’à l’IND, la conception et le management d'essais cliniques.

Lire la suite
SOLO-Pharmaco-Imaging
Service
28/06/2021

Oncodesign lance sa nouvelle offre de service DRIVE-MRT™ en partenariat avec Covalab, CheMatech et ABX-CRO

[Communiqué de Presse] L’alliance stratégique pour DRIVE-MRT™ (Molecular RadioTherapy) : ensemble du processus de Drug Discovery spécialisé en radiothérapie systémique ciblée (Théranostique)

Lire la suite
Biotech
24/06/2021

Oncodesign fait le point sur ses avancées sur RIPK2

[Communiqué de Presse] Retrouver l'actualisation du programme RIPK2 et au démarrage de nouveaux programmes associés à Nanocyclix.

Lire la suite
Finance
24/06/2021

Oncodesign met à disposition des informations relatives à l’Assemblée Générale des actionnaires du 24 juin 2021

Lire
Financial Result oncodesign
Finance
18/06/2021

Oncodesign maintains its revenue and operating income at €38 million in 2020…

[Press Release] Oncodesign maintains its revenue and operating income at €38 million in 2020 and is anticipating an operating profit for the 2nd straight year, within the context of the global public health crisis

Lire la suite
Biotech
14/06/2021

Maladie de Parkinson : Servier et Oncodesign annoncent la sélection d’un candidat préclinique

Lire la suite
portefeuille produits recherche developpement biotech
I.A.
18/05/2021

Exploitation des données pour la Drug Discovery : InterSystems et Oncodesign s’allient

Lire la suite
Finance
18/05/2021

Oncodesign & InterSystems s’allient pour optimiser l’exploitation des données dans le but de fiabiliser et d’accélérer son processus de Drug Discovery en oncologie

Lire
Finance
08/04/2021

Oncodesign enregistre pour la deuxième année consécutive, une rentabilité positive et double son résultat d’exploitation dans le contexte de la crise sanitaire

Lire
Finance
08/04/2021

Oncodesign enregistre pour la deuxième année consécutive, une rentabilité positive et double son résultat d’exploitation dans le contexte de la crise sanitaire

Lire
Finance
28/01/2021

Oncodesign maintient ses revenus et produits d’exploitation à 38 M€ en 2020 et anticipe un résultat d’exploitation positif pour la deuxième année consécutive, dans le contexte de la crise sanitaire mondiale

Lire
Finance
17/12/2020

[Communiqué de presse] Oncodesign annonce un plan d’actionnariat pour tous les salariés à l’occasion des 25 ans du Groupe

Lire
Finance
03/11/2020

Oncodesign annonce la signature d’un contrat de Drug Discovery avec ViraTherapeutics, filiale de Boehringer Ingelheim

Lire
Finance
06/10/2020

Oncodesign obtient un financement non-dilutif de 15,9 M€ sous forme de Prêt Garanti par l’État dans le contexte de la pandémie COVID-19

Lire
Finance
01/10/2020

Oncodesign : résultats du 1er semestre 2020

Lire
Finance
10/09/2020

Oncodesign annonce une augmentation de capital réservée au Comité de Direction de la Société

Lire
Finance
23/07/2020

Oncodesign annonce son chiffre d’affaires du 1er semestre et sa position de trésorerie en forte hausse au 30 juin 2020

Lire
Finance
07/07/2020

Procès-verbal des délibérations de l’assemblée générale mixte du 25 juin 2020

Lire
Finance
18/06/2020

Formulaire de Vote – Assemblée Générale 25 Juin 2020

Lire
Finance
18/06/2020

Rapport Gouvernement Entreprise 31.12.2019 – Assemblée Générale 25 Juin 2020

Lire
Finance
18/06/2020

Rapport sur les comptes annuels – Assemblée Générale 25 Juin 2020

Lire
Finance
18/06/2020

Rapport sur les comptes consolidés – Assemblée Générale 25 Juin 2020

Lire
Finance
03/06/2020

Publication d’une étude d’initiation de couverture par PORTZAMPARC, dans le cadre du suivi du titre en bourse

Lire
Finance
20/05/2020

Oncodesign et HitGen annoncent un partenariat stratégique dans le cadre de leur nouvelle offre de service commune de « drug discovery » intégrée (IDDS)

Lire
Finance
20/04/2020

Création de la nouvelle Business Unit « Intelligence Artificielle » et son nouveau Directeur

Lire
Finance
09/04/2020

2019 : des résultats annuels en très forte amélioration

Lire
Finance
12/03/2020

Bilan semestriel du contrat de liquidité confié à la société Louis Capital Markets

Lire
Biotech
17/02/2020

Oncodesign et Servier franchissent une première étape majeure dans le développement de leur programme LRRK2 pour la maladie de Parkinson

Lire
Finance
20/01/2020

Oncodesign annonce une hausse de 33% de son chiffre d’affaire 2019 et l’atteinte de son objectif d’équilibre financier avec 1 an d’avance

Lire
Finance
17/12/2019

Oncodesign annonce la sélection de son candidat-médicament First-in-Class, inhibiteur de la kinase RIPK2, pour les maladies auto-immunes et inflammatoires

Lire le communiqué
Finance
24/10/2019

Oncodesign annonce la publication d’un article présentant des résultats prometteurs pour le traitement du syndrome de l’homme de pierre (FOP)

Lire le communiqué
Finance
25/07/2019

Accélération de la croissance du Chiffre d’affaires au 1er semestre 2019 : +52% à 14 M€

Lire le communiqué
Finance
25/06/2019

Oncodesign atteint une étape déterminante dans le développement de son programme RIPK2

Lire le communiqué
Finance
11/03/2019

Maladie de Parkinson : Servier et Oncodesign s’associent pour explorer une nouvelle piste de recherche

Lire le communiqué
Finance
31/01/2019

Oncodesign annonce une forte croissance de ses revenus d’exploitation en 2018, pour la deuxième année consécutive : +20% à 31,1 M€

Lire le communiqué
Finance
18/12/2017

Résultats cliniques prometteurs pour le radiotraceur innovant anti-EGFR muté chez des patients atteints de cancer du poumon non à petites cellules

Lire le communiqué
Finance
05/12/2017

Oncodesign annonce des résultats positifs pour son programme MNK1/2

Lire le communiqué
Finance
15/11/2017

Oncodesign annonce avoir obtenu des résultats positifs permettant d’avancer le programme ALK1 en phase d’optimisation

Lire le communiqué
Finance
18/10/2017

Démarrage officiel du projet d’intelligence artificielle OncoSNIPE®

Lire le communiqué
Finance
05/10/2017

Oncodesign lance son nouveau site internet

Lire le communiqué
Finance
19/09/2017

Résultats du 1er semestre 2017

Lire le communiqué
Finance
31/08/2017

Oncodesign annonce l’acquisition des activités de services pharmaceutiques et biotechs de Bertin Pharma

Lire le communiqué
Finance
20/07/2017

Chiffre d’affaires du 1er semestre 2017 stable

Lire le communiqué
Finance
10/05/2017

Oncodesign entre en négociation exclusive avec Bertin Pharma pour l’acquisition d’activités de services

Lire le communiqué
Finance
11/04/2017

Oncodesign réaffirme son éligibilité au PEA-PME pour 2017/2018

Lire le communiqué
Finance
03/04/2017

Oncodesign présente ses dernières avancées scientifiques à l’occasion du congrès mondial en oncologie de l’AACR

Lire le communiqué
Finance
30/03/2017

Business update and FY 2016 results

Read
Finance
15/03/2017

Oncodesign reprend auprès d’Ipsen les droits sur son programme dans la maladie de Parkinson

Lire le communiqué
Finance
07/02/2017

Le projet collaboratif OncoSNIPE® d’Oncodesign bénéficie d’une aide de 7,7 millions d’euros du Programme d’investissements d’avenir (PIA) opéré par Bpifrance

Lire le communiqué
Finance
02/02/2017

Oncodesign annonce son calendrier financier pour l’année 2017

Lire le communiqué
Finance
31/01/2017

O